Back to Search Start Over

Hydroxyapatite as a biomaterial – a gift that keeps on giving.

Authors :
Ghiasi, Behrad
Sefidbakht, Yahya
Mozaffari-Jovin, Sina
Gharehcheloo, Behnaz
Mehrarya, Mehrnoush
Khodadadi, Arash
Rezaei, Maryam
Ranaei Siadat, Seyed Omid
Uskoković, Vuk
Source :
Drug Development & Industrial Pharmacy; Jul2020, Vol. 46 Issue 7, p1035-1062, 28p
Publication Year :
2020

Abstract

The synthetic analogue to biogenic apatite, hydroxyapatite (HA) has a number of physicochemical properties that make it an attractive candidate for diagnosis, treatment of disease and augmentation of biological tissues. Here we describe some of the recent studies on HA, which may provide bases for a number of new medical applications. The content of this review is divided to different medical application modes utilizing HA, including tissue engineering, medical implants, controlled drug delivery, gene therapies, cancer therapies and bioimaging. A number of advantages of HA over other biomaterials emerge from this discourse, including (i) biocompatibility, (ii) bioactivity, (iii) relatively simple synthesis protocols for the fabrication of nanoparticles with specific sizes and shapes, (iv) smart response to environmental stimuli, (v) facile functionalization and surface modification through noncovalent interactions, and (vi) the capacity for being simultaneously loaded with a wide range of therapeutic agents and switched to bioimaging modalities for uses in theranostics. A special section is dedicated to analysis of the safety of particulate HA as a component of parenterally administrable medications. It is concluded that despite the fact that many benefits come with the usage of HA, its deficiencies and potential side effects must be addressed before the translation to the clinical domain is pursued. Although HA has been known in the biomaterials world as the exemplar of safety, this safety proves to be the function of size, morphology, surface ligands and other structural and compositional parameters defining the particles. For this reason, each HA, especially when it comes in a novel structural form, must be treated anew from the safety research angle before being allowed to enter the clinical stage. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
03639045
Volume :
46
Issue :
7
Database :
Complementary Index
Journal :
Drug Development & Industrial Pharmacy
Publication Type :
Academic Journal
Accession number :
144501267
Full Text :
https://doi.org/10.1080/03639045.2020.1776321